Bifogade filer
SenzaGen presents and hosts a panel discussion at the SOT Annual Meeting & ToxExpo 2024
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen, which develops and sells non-animal chemical tests based on genomics and machine learning, announces today that the company will hold presentations and organize a round-table discussion at the SOT Annual Meeting & ToxExpo, the world's largest conference in toxicology, taking place in Salt Lake City, USA, from March 10 to 14, 2024.
The conference is organized by the American organization The Society of Toxicology and is expected to gather around 5,000 scientists and toxicologists from all over the world.
During the event, SenzaGen's team and collaborative partners will present the GARD® test platform for in vitro skin sensitization, emphasizing its broad applicability, relevance for medical devices, and ability to provide quantitative information about safe dose levels.
Moreover, SenzaGen will facilitate a panel discussion on the evolving trends in skin sensitization and in vitro testing. The expert panel will include representatives from L’Oréal, the American Research Institute for Fragrance Materials (RIFM), and the ISO working group for skin irritation and skin sensitization.
Scientific program
March 12, 9:00–10:00
Presentation and round-table discussion on new alternative methods (NAMs) and industry trends
Advancing NAMs for Skin Sensitization Testing: Medical Devices and Quantitative Potency Assessment
Expert Panel:
- Dr Nathalie Alépée, Research Scientific Officer, L’Oréal Research & Innovation
- Dr Isabelle Lee, Senior Scientist, Research Institute for Fragrance Materials, Inc. (RIFM)
- Dr Christian Pellevoisin, Toxicologist, Urbilateria, Convenior of the WG8 skin irritation and sensitization of the ISO/TC194 for biocompatibility of medical devices
- Dr Henrik Johansson, Chief Scientist, SenzaGen
March 11–12
Posters on GARD®
Spotlight on PoD, NESILs, product development and CE-marking of Medical Devices
Joint poster with L’Oréal
P739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response
Joint poster with Sonova
P487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay
Joint poster with Duearity
P480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment
Joint poster presented by RIFM
P318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay
Joint poster presented by IFF
P762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products
Joint poster presented by Inotiv
P738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard
Visit us at booth #732
Our team of GARD® experts will be on hand at booth #732 to engage in discussions and answer any inquiries regarding in vitro toxicology.
SOT webpage
For additional details on the conference, please refer to the official website of the 63rd SOT Annual Meeting & ToxExpo.